Basic Information
| RNALocate ID: | RLID:11002386 |
| RNA Symbol: | hsa-miR-130b-3p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-130b-3p |
| RNA ID: | miRBase:MIMAT0000691 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 30542726 |
| Tissue/Cell Line: | HCC tissues |
| Method: | RNA sequencing |
|
Differentially expressed exosomal miRs between the fast- and slow-migrated groups. Originally published in Oncol Rep. Yu LX, et al, 2019. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
| Description: | Six exosomal miRNAs were differentially expressed between the fast- and slow-migrated groups. In the fast-migrated group, five miRNAs (miR-140-3p, miR-30d-5p, miR-29b-3p, miR-130b-3p and miR-330-5p) were downregulated, and one miRNA (miR-296-3p) was upregulated (Fig. 4B). |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002002 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01002003 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:11002385 | Exosome | Pooled sera | 27278097 |
| RLID:11002387 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11002388 | Exosome | Renal cancer cells | 21670082 |
| RLID:11002389 | Exosome | Brain tissue | 23382797 |
| RLID:11002390 | Exosome | Plasma | 23663360 |
| RLID:11002391 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11002392 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
| RLID:11002393 | Extracellular vesicle | HEK-293T cells | 22849433 |
| RLID:11002394 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000114 | Exosome | B lymphoblastoid cells|Endothelial cells|Kidney tissue|Lymphoma tissue | |
| RLID-D:11000403 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-130b-3p | Idiopathic pulmonary fibrosis | MNDR-E-MI-10892 |
| MNDR | hsa-miR-130b-3p | Splenic marginal zone lymphoma | MNDR-E-MI-10893 |
| MNDR | hsa-miR-130b-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-10894 |
| MNDR | hsa-miR-130b-3p | Oral squamous cell carcinoma | MNDR-E-MI-10895 |
| MNDR | hsa-miR-130b-3p | Large cell neuroendocrine cancer | MNDR-E-MI-10896 |
| MNDR | hsa-miR-130b-3p | Medulloblastoma | MNDR-E-MI-10897 |
| MNDR | hsa-miR-130b-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-10898 |
| MNDR | hsa-miR-130b-3p | Ovarian clear cell carcinoma | MNDR-E-MI-10899 |
| MNDR | hsa-miR-130b-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-10900 |
| MNDR | hsa-miR-130b-3p | Lymphoma | MNDR-E-MI-10901 |
| MNDR | hsa-miR-130b-3p | Lymphoma non-hodgkin | MNDR-E-MI-10902 |
| MNDR | hsa-miR-130b-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-10903 |
| MNDR | hsa-miR-130b-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-10904 |
| MNDR | hsa-miR-130b-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-10905 |
| MNDR | hsa-miR-130b-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-10906 |
| MNDR | hsa-miR-130b-3p | Her2-receptor positive breast cancer | MNDR-E-MI-10907 |
| MNDR | hsa-miR-130b-3p | Breast cancer luminal | MNDR-E-MI-10908 |
| MNDR | hsa-miR-130b-3p | Niemann-pick disease type c | MNDR-E-MI-10909 |
| MNDR | hsa-miR-130b-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-10910 |
| MNDR | hsa-miR-130b-3p | Lupus nephritis | MNDR-E-MI-10911 |
| MNDR | hsa-miR-130b-3p | B cell acute lymphoblastic leukemia | MNDR-E-MI-10912 |
| MNDR | hsa-miR-130b-3p | Prostate cancer | MNDR-E-MI-10913 |
| MNDR | hsa-miR-130b-3p | Gastric cancer | MNDR-E-MI-10914 |
| MNDR | hsa-miR-130b-3p | Alzheimer disease | MNDR-E-MI-10915 |
| MNDR | hsa-miR-130b-3p | Intracranial aneurysm | MNDR-E-MI-10916 |
| MNDR | hsa-miR-130b-3p | Bladder cancer | MNDR-E-MI-10917 |
| MNDR | hsa-miR-130b-3p | Esophageal carcinoma | MNDR-E-MI-10918 |
| MNDR | hsa-miR-130b-3p | Dysautonomia familial | MNDR-E-MI-10919 |
| MNDR | hsa-miR-130b-3p | Head and neck cancer | MNDR-E-MI-10920 |
| MNDR | hsa-miR-130b-3p | Leukemia | MNDR-E-MI-10921 |
| MNDR | hsa-miR-130b-3p | Huntington disease | MNDR-E-MI-10922 |
| MNDR | hsa-miR-130b-3p | Cardiovascular disease | MNDR-E-MI-10923 |
| MNDR | hsa-miR-130b-3p | Carotid stenosis | MNDR-E-MI-10924 |
| MNDR | hsa-miR-130b-3p | Lung cancer | MNDR-E-MI-10925 |
| MNDR | hsa-miR-130b-3p | Endometrial cancer | MNDR-E-MI-10926 |
| MNDR | hsa-miR-130b-3p | Parkinson disease | MNDR-E-MI-10927 |
| MNDR | hsa-miR-130b-3p | Niemann-pick disease | MNDR-E-MI-10928 |
| MNDR | hsa-miR-130b-3p | Basal-like breast cancer | MNDR-E-MI-10929 |
| MNDR | hsa-miR-130b-3p | Pituitary neoplasms | MNDR-E-MI-10930 |
| MNDR | hsa-miR-130b-3p | Pancreatic cancer | MNDR-E-MI-10931 |
| MNDR | hsa-miR-130b-3p | Melanoma | MNDR-E-MI-10932 |
| MNDR | hsa-miR-130b-3p | Rectum adenocarcinoma | MNDR-E-MI-10933 |
| MNDR | hsa-miR-130b-3p | Nephroblastoma | MNDR-E-MI-10934 |
| MNDR | hsa-miR-130b-3p | Colon cancer | MNDR-E-MI-10935 |
| MNDR | hsa-miR-130b-3p | Ischemic attack transient | MNDR-E-MI-10936 |
| MNDR | hsa-miR-130b-3p | Colon adenocarcinoma | MNDR-E-MI-10937 |
| MNDR | hsa-miR-130b-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-10938 |
| MNDR | hsa-miR-130b-3p | Ovarian cancer | MNDR-E-MI-10939 |
| MNDR | hsa-miR-130b-3p | Prostate adenocarcinoma | MNDR-E-MI-10940 |
| MNDR | hsa-miR-130b-3p | Carcinoma ductal breast | MNDR-E-MI-10941 |
| MNDR | hsa-miR-130b-3p | Glioblastoma | MNDR-E-MI-10942 |
| MNDR | hsa-miR-130b-3p | Glioma | MNDR-E-MI-10943 |
| MNDR | hsa-miR-130b-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-10944 |
| MNDR | hsa-miR-130b-3p | Epilepsy temporal lobe | MNDR-E-MI-10945 |
| MNDR | hsa-miR-130b-3p | Osteosarcoma | MNDR-E-MI-10946 |
| MNDR | hsa-miR-130b-3p | Breast carcinoma | MNDR-E-MI-10947 |
| MNDR | hsa-miR-130b-3p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-10948 |
| MNDR | hsa-miR-130b-3p | Uterine cancer | MNDR-E-MI-10949 |
| MNDR | hsa-miR-130b-3p | Gastric adenocarcinoma | MNDR-E-MI-10950 |
| MNDR | hsa-miR-130b-3p | Cervical squamous cell carcinoma | MNDR-E-MI-10951 |
| MNDR | hsa-miR-130b-3p | Bone-invasive pituitary adenoma | MNDR-E-MI-10952 |
| MNDR | hsa-miR-130b-3p | Lung squamous cell carcinoma | MNDR-E-MI-10953 |
| MNDR | hsa-miR-130b-3p | Carcinoma lung non-small-cell | MNDR-E-MI-10954 |
| MNDR | hsa-miR-130b-3p | Lung adenocarcinoma | MNDR-E-MI-10955 |
| MNDR | hsa-miR-130b-3p | Adrenocortical carcinoma | MNDR-E-MI-10956 |
| MNDR | hsa-miR-130b-3p | Thyroid carcinoma | MNDR-E-MI-10957 |
| MNDR | hsa-miR-130b-3p | Ovarian carcinoma | MNDR-E-MI-10958 |
| MNDR | hsa-miR-130b-3p | Bladder urothelial carcinoma | MNDR-E-MI-10959 |
| MNDR | hsa-miR-130b-3p | Pancreatic adenocarcinoma | MNDR-E-MI-10960 |
| MNDR | hsa-miR-130b-3p | Systemic scleroderma | MNDR-E-MI-10961 |
| MNDR | hsa-miR-130b-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-10962 |
| MNDR | hsa-miR-130b-3p | Carcinoma renal cell | MNDR-E-MI-10963 |
| MNDR | hsa-miR-130b-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-10964 |
| MNDR | hsa-miR-130b-3p | Clear cell renal cell carcinoma | MNDR-E-MI-10965 |
| MNDR | hsa-miR-130b-3p | Large cell carcinoma | MNDR-E-MI-10966 |
| MNDR | hsa-miR-130b-3p | Biliary tract cancer | MNDR-E-MI-10967 |
| MNDR | hsa-miR-130b-3p | Cholangiocarcinoma | MNDR-E-MI-10968 |
| MNDR | hsa-miR-130b-3p | Esophageal cancer | MNDR-E-MI-10969 |
| MNDR | hsa-miR-130b-3p | Lung small cell carcinoma | MNDR-E-MI-10970 |
| MNDR | hsa-miR-130b-3p | Synovial sarcoma | MNDR-E-MI-10971 |
| MNDR | hsa-miR-130b-3p | Stomach carcinoma | MNDR-E-MI-10972 |
| MNDR | hsa-miR-130b-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-10973 |
| MNDR | hsa-miR-130b-3p | Testicular germ cell cancer | MNDR-E-MI-10974 |
| MNDR | hsa-miR-130b-3p | T acute lymphoblastic leukemia | MNDR-E-MI-10975 |
| MNDR | hsa-miR-130b-3p | Acute t cell leukemia | MNDR-E-MI-10976 |
| MNDR | hsa-miR-130b-3p | Fibromyalgia | MNDR-E-MI-10977 |
| MNDR | hsa-miR-130b-3p | Breast invasive carcinoma | MNDR-E-MI-10978 |
| MNDR | hsa-miR-130b-3p | Hepatocellular carcinoma | MNDR-E-MI-10979 |
| MNDR | hsa-miR-130b-3p | B-cell lymphoma | MNDR-E-MI-10980 |
| MNDR | hsa-miR-130b-3p | Rheumatoid arthritis | MNDR-E-MI-10981 |
| MNDR | hsa-miR-130b-3p | T-cell leukemia | MNDR-E-MI-10982 |
| MNDR | hsa-miR-130b-3p | Hodgkin lymphoma | MNDR-E-MI-10983 |
| MNDR | hsa-miR-130b-3p | Burkitt lymphoma | MNDR-E-MI-10984 |
| MNDR | hsa-miR-130b-3p | Dementia vascular | MNDR-E-MI-10985 |
| MNDR | hsa-miR-130b-3p | Neuromyelitis optica | MNDR-E-MI-10986 |
| MNDR | hsa-miR-130b-3p | Skin cutaneous melanoma | MNDR-E-MI-10987 |
| MNDR | hsa-miR-130b-3p | Skin melanoma | MNDR-E-MI-10988 |
| MNDR | hsa-miR-130b-3p | Acute myelogenous leukemia | MNDR-E-MI-10989 |
| MNDR | hsa-miR-130b-3p | Colorectal cancer | MNDR-E-MI-10990 |
| MNDR | hsa-miR-130b-3p | Multiple myeloma | MNDR-E-MI-10991 |
| MNDR | hsa-miR-130b-3p | Ovarian epithelial cancer | MNDR-E-MI-10992 |
| MNDR | hsa-miR-130b-3p | Diabetic nephropathies | MNDR-E-MI-10993 |
| MNDR | hsa-miR-130b-3p | Ependymoma | MNDR-E-MI-10994 |
| MNDR | hsa-miR-130b-3p | Prostatic neoplasms | MNDR-E-MI-10995 |
| MNDR | hsa-miR-130b-3p | Epstein-barr virus infections | MNDR-E-MI-10996 |
| MNDR | hsa-miR-130b-3p | Stroke lacunar | MNDR-E-MI-10997 |
| MNDR | hsa-miR-130b-3p | Breast cancer her3+ negative | MNDR-E-MI-10998 |
| MNDR | hsa-miR-130b-3p | Duke A | MNDR-E-MI-10999 |
| MNDR | hsa-miR-130b-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-11000 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ACVR1 | Homo sapiens | RR00038728 |
TOP